The 15-Day Clock: Common Mistakes in Serious Adverse Reaction Reporting and How Australian Sponsors Can Avoid Them

In pharmacovigilance, timing matters. A serious adverse reaction may need to be reported to the Therapeutic Goods Administration (TGA) within 15 calendar days, but the real challenge for many medicine sponsors is understanding exactly when that reporting clock starts.

A report may initially be received by a customer service representative, sales employee, distributor, healthcare professional or external service provider. It may take several days before the information reaches the pharmacovigilance department. However, the reporting deadline does not wait for the information to reach the person responsible for pharmacovigilance.

For Australian sponsors, understanding the 15-day reporting requirement is essential to maintaining regulatory compliance and ensuring that important safety information reaches the TGA in a timely manner.

This article explores how the 15-day reporting clock works, what constitutes a reportable serious adverse reaction, and the common operational mistakes that can lead to late submissions.

1. What Is the 15-Day Reporting Requirement?

Under Australian pharmacovigilance requirements, sponsors of medicines included in the Australian Register of Therapeutic Goods (ARTG) must report serious adverse reactions occurring in Australia to the TGA as soon as possible and no later than 15 calendar days after receipt.

This requirement applies to both expected and unexpected serious adverse reactions.

In practical terms, this means that a sponsor cannot decide to report a reaction only because it is unexpected, nor can an already known adverse reaction automatically be excluded from reporting because it is listed in the product information or on the product label.

The reporting obligation applies to serious adverse reactions associated with the use of the sponsor's medicine, subject to the applicable reporting criteria.

It is also important to understand that the 15-day requirement refers to calendar days, not business days. Weekends and public holidays are included.

The key principle: the reporting clock starts when the sponsor first receives a valid serious adverse reaction report, not when the pharmacovigilance department processes it.

2. When Does Day 0 Start?

One of the most common sources of non-compliance is an incorrect understanding of Day 0.

According to TGA guidance, Day 0 is the date on which the four minimum data elements required for a valid adverse reaction report are received by any of the sponsor's personnel.

These four elements are:

  1. Identifiable patient: Information sufficient to establish that a real patient is involved, such as initials, age, sex or another patient identifier.

  2. Identifiable reporter: Information identifying the person providing the report, such as their name or contact details.

  3. Suspect medicine: The medicine suspected of being associated with the adverse reaction.

  4. Suspected adverse reaction: At least one identifiable adverse reaction or suspected clinical event.

Once these four elements have been received, the reporting clock starts.

Importantly, the information does not need to be received by the QPPV-A, Australian pharmacovigilance contact person or dedicated PV department.

For example:

A consumer contacts a company's customer service department on Monday and reports that they experienced severe abdominal pain and required hospitalisation after taking one of the company's listed medicines.

The customer provides their name, sufficient information to identify the patient, the product name and a description of the reaction.

The customer service representative records the complaint and forwards it to the company's quality department three days later. The quality department then sends it to the external pharmacovigilance provider another two days later.

In this situation, Day 0 is Monday, when the four minimum data elements were first received by the customer service representative.

The sponsor cannot restart the clock when the report reaches the quality department or the external PV provider.

This is why effective internal communication and clear safety information escalation procedures (including internal timelines) are essential.

3. What Qualifies as a Serious Adverse Reaction?

Not every adverse reaction requires submission to the TGA within 15 days.

The expedited reporting requirement applies to serious adverse reactions.

According to TGA guidance, a serious adverse reaction is a medical occurrence associated with the use of a medicine that, at any dose:

  • Results in death.

  • Is life-threatening.

  • Requires inpatient hospitalisation or prolongation of existing hospitalisation.

  • Results in persistent or significant disability or incapacity.

  • Is associated with a congenital anomaly or birth defect.

  • Is considered a medically important event or reaction.

The last category is particularly important because an adverse reaction does not necessarily need to result in hospitalisation or a life-threatening outcome to be considered serious.

A medically important event may require medical intervention to prevent one of the serious outcomes listed above.

Sponsors should also understand the distinction between seriousness and severity.

Severity describes the intensity of a reaction, whereas seriousness is a regulatory classification based on the medical outcome or significance of the event.

For example, a severe headache may be classified as non-serious if it does not meet any seriousness criteria. Conversely, an adverse reaction that requires hospitalisation may be serious even if its clinical intensity is not described as severe.

Seriousness should therefore be assessed independently of causality and the intensity of the symptoms.

Where information about the outcome or treatment is incomplete, the TGA recommends taking a conservative approach.

4. Five Common Mistakes That Can Lead to Late Reporting

Even organisations with established pharmacovigilance procedures can experience reporting delays. The following mistakes are particularly relevant to Australian medicine sponsors.

Mistake 1: Starting the Clock When the PV Department Receives the Report

This is arguably one of the most important compliance risks.

A serious adverse reaction may initially be reported to customer service, sales representatives, medical information personnel, distributors or other company employees.

If these individuals do not promptly forward the information to the appropriate PV contact, the sponsor may unknowingly exceed the reporting deadline.

How to avoid it:

Sponsors should establish clear procedures requiring all employees who may receive safety information to forward it to the designated pharmacovigilance contact immediately.

Employees should receive appropriate training on recognising potential adverse reactions, capturing the relevant information and escalating reports without delay.

The reporting process should cover all relevant departments, not just those directly involved in pharmacovigilance.

Mistake 2: Waiting for a Complete Medical Report Before Starting the Process

Another common misconception is that the sponsor must obtain a complete medical history, hospital discharge summary or confirmation from the treating doctor before submitting a serious adverse reaction report.

This is incorrect.

Once the four minimum data elements have been received, the reporting clock starts. The sponsor should make reasonable attempts to obtain additional information, but these follow-up activities must not delay the initial submission beyond the applicable deadline.

Where additional clinical information is unavailable, the sponsor should submit the information available and continue appropriate follow-up.

How to avoid it:

Establish a procedure that distinguishes between the minimum information required to validate a case and the additional information desirable for a comprehensive medical assessment.

Ensure that follow-up activities are performed in parallel with preparation of the initial report rather than being treated as a prerequisite for submission.

Mistake 3: Reporting Only Unexpected Serious Adverse Reactions

Some sponsors mistakenly assume that only previously unknown or unexpected adverse reactions need to be reported to the TGA.

However, Australian reporting requirements apply to both expected and unexpected serious adverse reactions occurring in Australia.

For example, if a product label already identifies a particular serious adverse reaction, a new report of that reaction may still be subject to the 15-day reporting requirement.

How to avoid it:

Ensure that internal reporting criteria reflect Australian regulatory requirements and do not automatically exclude serious adverse reactions simply because they are already documented in the product information or label.

Mistake 4: Assuming That Outsourced Pharmacovigilance Transfers the Reporting Responsibility

Many Australian medicine sponsors outsource their pharmacovigilance activities to external providers.

While this can be an effective way to maintain a compliant PV system, outsourcing does not remove the sponsor's regulatory responsibilities.

If an adverse reaction is received by the sponsor, its distributor or another relevant party before it reaches the external PV provider, the original receipt date may determine the reporting deadline.

For example, a distributor receives a serious adverse reaction report but does not forward it to the sponsor for several days. The delay may compromise the sponsor's ability to meet the 15-day requirement.

How to avoid it:

Sponsors should establish clear written agreements and procedures defining:

  • Which parties are responsible for collecting adverse reaction reports.

  • How quickly safety information must be forwarded.

  • Who is responsible for initial case processing and assessment.

  • Who is responsible for submission to the TGA.

  • How follow-up information is communicated.

  • How reporting timelines are monitored and reconciled.

Safety information exchange arrangements should be sufficiently detailed to ensure that all parties understand their responsibilities.

Mistake 5: Forgetting That the Clock Can Restart Following Significant Follow-up Information

The reporting obligation does not necessarily end once the initial serious adverse reaction report has been submitted.

Additional clinically or medically relevant follow-up information may need to be reported to the TGA.

For example, a report initially describes a serious adverse reaction involving a patient who was hospitalised. Several days later, the sponsor receives new information confirming that the patient has developed a permanent disability.

This additional information may materially change the understanding of the case and must be assessed for regulatory reporting.

Under TGA guidance, the 15-calendar-day reporting timeframe restarts when significant additional clinical or medically relevant information is received.

How to avoid it:

Sponsors should establish procedures for identifying, assessing and reporting significant follow-up information.

The date of receipt of each relevant follow-up should be recorded, and the applicable reporting deadline should be monitored independently of the original submission.

5. What About Non-Serious Adverse Reactions?

Not every adverse reaction needs to be submitted individually to the TGA within 15 days.

Under the routine Australian requirements for ARTG medicines, non-serious adverse reaction reports are not generally subject to the same individual expedited reporting obligation as serious Australian adverse reactions.

However, this does not mean that sponsors can ignore or discard non-serious reports.

Sponsors must maintain appropriate records and provide the information to the TGA when requested. Non-serious adverse reactions must also be included in relevant PSUR summaries where a PSUR is required.

Furthermore, a pattern of non-serious reactions may reveal a significant safety issue or a change in the product's safety profile.

For example, an increasing number of reports describing the same adverse reaction may warrant investigation even if each individual case is classified as non-serious.

Sponsors should therefore maintain systems for collecting, documenting and reviewing all relevant safety information.

6. The 72-Hour Rule: An Important Distinction

The 15-day reporting requirement should not be confused with the separate notification requirement for significant safety issues.

Australian medicine sponsors must notify the TGA of significant safety issues within 72 hours of becoming aware of the issue.

A significant safety issue may involve a newly identified risk or a change in a known risk that has the potential to materially affect the safety profile or benefit-risk balance of a medicine.

For example, a sponsor may identify a cluster of serious adverse reactions suggesting a previously unrecognised risk associated with a particular ingredient.

Even if individual serious adverse reaction reports are being processed under the 15-day reporting requirement, the emerging safety issue may independently require notification to the TGA within 72 hours.

These are separate regulatory obligations, and meeting one does not automatically satisfy the other.

Sponsors should therefore have procedures to identify when individual case reporting also gives rise to a broader safety issue requiring escalation.

7. How Can Sponsors Demonstrate Compliance?

Meeting the reporting deadline is important, but sponsors must also be able to demonstrate that their processes are effective.

The TGA's pharmacovigilance inspection findings have identified delayed serious adverse reaction reporting, inadequate reporting procedures and deficiencies in record-keeping as recurring compliance concerns.

Sponsors should maintain sufficient documentation to reconstruct the reporting timeline for each serious adverse reaction.

At a minimum, this should include:

  • Initial receipt date: Establishes Day 0 and determines the start of the reporting clock.

  • Initial recipient: Identifies which employee or external party first received the report.

  • Date the four minimum criteria were available: Supports case validity and calculation of the reporting deadline.

  • Date received by the PV department: Identifies any internal escalation delays.

  • Date received by the external PV provider: Supports oversight of outsourced pharmacovigilance activities.

  • Date of initial TGA submission: Demonstrates whether the reporting deadline was met.

  • Submission acknowledgement: Confirms that the submission was received by the TGA.

  • Follow-up receipt dates: Supports monitoring of additional reporting deadlines.

  • Follow-up submission dates: Demonstrates compliance with follow-up reporting requirements.

Sponsors should also consider implementing routine safety data reconciliation between departments and external providers.

The TGA recommends that this reconciliation be undertaken routinely, preferably monthly, to verify that all adverse event reports and relevant safety information have been received and recorded.

This is particularly important where different departments or external organisations are involved in collecting and processing safety information.

8. A Practical Compliance Checklist for Australian Sponsors

The following checklist can help sponsors assess whether their current processes adequately address the 15-day reporting requirement.

  • All employees who may receive adverse reaction reports have received appropriate PV training.

  • Clear procedures exist for escalating safety information from all relevant departments.

  • Distributors and other relevant third parties understand their safety reporting obligations.

  • The organisation can identify the earliest date on which the four minimum case elements were received.

  • Seriousness assessments are performed consistently and independently of causality assessments.

  • Procedures distinguish between serious and non-serious adverse reactions.

  • The 15-calendar-day reporting deadline is monitored from the correct Day 0.

  • Initial submissions are not unnecessarily delayed while waiting for additional medical information.

  • Significant follow-up information is identified and reported within the applicable timeframe.

  • Potential significant safety issues are escalated separately under the 72-hour requirement.

  • Safety data are routinely reconciled between internal departments and external PV providers.

  • Submission records and supporting documentation are retained.

The 15-day reporting requirement may appear straightforward, but maintaining compliance requires more than simply submitting serious adverse reaction reports to the TGA within a specified timeframe.

Sponsors must understand when Day 0 starts, ensure that safety information is promptly escalated from all relevant sources, apply the correct seriousness criteria and maintain oversight of initial and follow-up submissions.

For smaller Australian medicine sponsors, particularly those marketing complementary and listed medicines, these processes do not need to be unnecessarily complicated. However, they must be clearly defined, consistently implemented and supported by appropriate training and documentation.

Ultimately, the 15-day clock starts when the sponsor first receives the required information, not when someone in the PV department opens the email.

In pharmacovigilance, a delay in communication can quickly become a regulatory compliance issue.

Next
Next

An Adverse Event Is Not Always Obvious: A Practical Guide for Australian Listed Medicine Sponsors